FRA/NOV1 (FRA/NOV1)

Frankfurt Stock Exchange: FRA/NOV1 · EUR

€10.6

+0.00 (0.0%)· Recorded snapshot

Market cap	153.6B
Revenue (ttm)	44.1B
Net income (ttm)	15.6B
EPS (ttm)	€1.07
P/E (trailing)	9.9x
P/E (forward)	11.7x
Volume	0

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 44.1B
Net income (ttm): 15.6B
EPS (ttm): €1.07
P/E (trailing): 9.9x
P/E (forward): 11.7x
Market cap: 153.6B

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E11.7

P25 n/aP50 n/aP75 n/a

Trailing P/E9.9

P25 n/aP50 n/aP75 n/a

ROE59.8

P25 n/aP50 n/aP75 n/a

ROIC39.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All FRA/NOV1 indicators

Market & fundamental data

Available fields

222

Groups with data

Currency

DKK

Showing 222 of 222 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	EUR
Country	Denmark
Country code	DE
Earnings date	2026-11-04
Employees	66,700
Employees change	-9,506
Employees growth	-12.28%
Enterprise value	EUR 166.3B
Exchange	Frankfurt Stock Exchange
Financial currency	DKK
Financial report date	2026-06-30
First seen	2026-07-12
Fiscal year end	December
Founded	1923
Industry	Drug Manufacturers - General
Is primary listing	No
ISIN number	CA67010P1018
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Market cap	EUR 153.6B
Next earnings date	2026-11-04
Price	EUR 10.60
Price currency	EUR
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-27
Symbol	fra/NOV1
Website	https://www.novonordisk.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	25.52x
Average P/E ratio (3Y)	26.67x
Average P/E ratio (5Y)	30.16x
Earnings yield	10.1%
EV/Earnings	10.68x
EV/EBIT	7.7x
EV/EBITDA	7.09x
EV/FCF	16.39x
EV/Sales	3.77x
FCF / EV yield	6.1%
FCF yield	6.61%
Forward P/E	11.69x
Graham number	7.02973
Graham upside	-33.68%
Lynch fair value	EUR 22.89
Lynch upside	115.91%
P/(FCF - SBC) ratio	15.43x
P/(OCF - SBC) ratio	8.8x
P/B ratio	5.19x
P/E ratio	9.91x
P/FCF ratio	15.14x
P/OCF ratio	8.71x
P/S ratio	3.49x
Price / tangible book value	11.57x
Price/EBITDA ratio	6.61x
Sector forward P/E	14.8x
Sector P/E	39.91x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	48.99%
EBITDA margin	52.72%
Effective tax rate	21.72%
FCF margin	23.02%
Gross margin	81.99%
Operating margin	48.99%
Pretax margin	45.15%
Profit margin	35.35%
Profit per employee	EUR 233,507
Profitable quarters	164
Profitable years	41
Revenue per employee	EUR 660,619
ROA	18.73%
ROA (5Y)	21.35%
ROCE	45.35%
ROE	59.82%
ROE (5Y)	74.56%
ROIC	39.22%
ROIC (5Y)	68.16%
SBC / revenue	0.44%
Tax / revenue	9.81%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	4.98%
EPS growth (Q)	-20.61%
EPS growth (QoQ)	-56.63%
EPS growth 10Y	14.01%
EPS growth 3Y	20.74%
EPS growth 5Y	22.33%
EPS growth years	31
FCF growth	14.3%
FCF growth (Q)	56.84%
FCF growth (QoQ)	232.92%
FCF growth 3Y	2.24%
FCF growth 5Y	9.51%
Gross profit growth	2.76%
Gross profit growth (Q)	-4.1%
Gross profit growth 3Y	16.73%
Gross profit growth 5Y	20.17%
Net income growth	4.84%
Net income growth (Q)	-20.81%
Net income growth (QoQ)	-56.77%
Net income growth 3Y	20.09%
Net income growth 5Y	21.29%
Net income growth years	38
OCF growth	7.52%
OCF growth (Q)	32.14%
OCF growth (QoQ)	129.19%
OCF growth 10Y	11.56%
OCF growth 3Y	13.7%
OCF growth 5Y	19.47%
Operating income growth	9.29%
Operating income growth (Q)	-0.18%
Operating income growth 3Y	22.91%
Operating income growth 5Y	24.43%
Revenue growth	5.61%
Revenue growth (Q)	2.12%
Revenue growth (QoQ)	-18.94%
Revenue growth 10Y	11.56%
Revenue growth 3Y	17.84%
Revenue growth 5Y	20.45%
Revenue growth quarters	2
Revenue growth years	8

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	EUR -7.5B
Depreciation and amortization	EUR 1.6B
EBIT	EUR 21.6B
EBITDA	EUR 23.2B
EPS	EUR 1.07
Financing cash flow	EUR -3B
Free cash flow	EUR 10.1B
Free cash flow minus SBC	EUR 10B
Gross profit	EUR 36.1B
Income taxes	EUR 4.3B
Investing cash flow	EUR -11.2B
Net borrowing	EUR 4.9B
Net cash flow	EUR 3.5B
Net income	EUR 15.6B
Operating cash flow minus SBC	EUR 17.4B
Operating income	EUR 21.6B
Revenue	EUR 44.1B
Stock-based compensation	EUR 191.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	4.21
Book value per share	EUR 6.68
Debt / EBITDA	0.8
Debt / equity	0.63
Debt / FCF	1.85
Goodwill	EUR 2.7B
Interest coverage	1,566.84
Long-term assets	EUR 51.7B
Long-term liabilities	EUR 18B
Net cash (debt)	EUR -12.7B
Net cash / market cap	-8.29%
Net debt / EBITDA	0.55
Net debt / equity	0.43
Net debt / FCF	1.25
Piotroski F-Score	5
Property, plant and equipment	EUR 31B
Shareholders' equity	EUR 29.6B
Tangible book value	EUR 13.3B
Tangible book value per share	EUR 3.00
Total assets	EUR 79.6B
Total cash	EUR 6B
Total debt	EUR 18.7B
Total liabilities	EUR 50B

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.61
Current assets	EUR 27.9B
Current liabilities	EUR 32B
Current ratio	0.87
Inventory turnover	1.22
Net working capital	EUR -7.6B
Quick ratio	0.64
Working capital	EUR -4.1B
Working capital turnover	-1.17

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.14%
Payout ratio	44.64%
Shareholder yield	0.14%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	EUR 10.93
1D price change	0%
1M price change	-2.75%
1M total return	-2.75%
1W price change	3.92%
1W total return	3.92%
20-day SMA	EUR 10.07
200-day SMA	EUR 11.31
3M price change	-13.82%
3M total return	-13.82%
50-day SMA	EUR 10.71
50-day SMA vs 200-day SMA	50under200
52-week high	EUR 16.20
52-week high date	2026-01-19
52-week low	EUR 8.85
52-week low date	2026-03-02
6M price change	11%
6M total return	11%
All-time high	EUR 16.20
All-time high date	2026-01-12
All-time low	EUR 8.85
All-time low date	2026-03-02
Average true range (ATR)	EUR 0.30
Average volume	2.5
Change from 52-week high	-34.57%
Change from 52-week low	19.77%
Change from all-time high	-34.57%
Change from all-time low	19.77%
Change from open	2.91%
Day's gap	-2.83%
High price	EUR 10.60
Low price	EUR 10.30
Monthly RSI	0
Open price	EUR 10.30
Position in 52-week range	100%
Previous close	EUR 10.60
Price vs 150-day SMA	-3.02%
Price vs 20-day SMA	5.23%
Price vs 200-day SMA	-6.25%
Price vs 50-day SMA	-1%
Relative volume	5
RSI	54.94
Sharpe ratio	0.03
Sortino ratio	0.12
Volume	0
Weekly RSI	46.72
YTD price change	-15.2%
YTD total return	-15.2%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	3.2B
Shares change (QoQ)	-0.29%
Shares change (YoY)	-0.14%
Shares held by insiders	0.02%
Shares held by institutions	27.53%

Deeper analysis on FRA/NOV1

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this FRA/NOV1 report

Is a complete FRA/NOV1 research report available?

No complete published report is available for fra/NOV1 (FRA/NOV1) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

FRA/NOV1 (FRA/NOV1)

Price

Financial snapshot

Fair-value bridge

Latest news · FRA/NOV1

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All FRA/NOV1 indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on FRA/NOV1

Frequently asked questions